HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of high-dose chemotherapy and autologous stem cell transplant for recurrent Wilms' tumor: a meta-analysis.

AbstractSUMMARY:
Long-term survival of relapsed Wilms' tumor patients is about 40% to 70%. Modern second-line treatment consists of either (a) salvage chemotherapy+/-radiation therapy (CT) or (b) chemotherapy followed by high-dose chemotherapy and autologous hematopoietic stem cell rescue (ASCR). Here, we conduct an individual patient data meta-analysis on 100 patients collected from 6 studies to determine characteristics that predict survival in relapsed patients who received ASCR therapy. We compare these results with survival data on 118 CT treated patients from 2 recently published studies. Four year overall survival among the combined ASCR treated patients was 54.1% (95% CI: 42.8-64.1%). The ASCR patients who only relapsed in the lungs had higher 4-years survival rates 77.7% (58.6% to 88.8%) than those who relapsed in other locations and/or suffered multiple relapses 41.6% (24.8% to 57.6%). Although lung-only relapse is considered a favorable prognostic factor, there was no clear advantage for the patients treated with salvage chemotherapy. Four-year survival rates among stage I-II patients were about 30% higher with CT than ASCR, but the 2 were comparable for stage III-IV patients. These findings suggest salvage chemotherapy is typically the better choice for relapsed Wilms' tumor patients, ASCR could be considered for stage III-IV patients with a lung-only relapse.
AuthorsAngela Presson, Theodore B Moore, Pamela Kempert
JournalJournal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 32 Issue 6 Pg. 454-61 (Aug 2010) ISSN: 1536-3678 [Electronic] United States
PMID20505538 (Publication Type: Journal Article, Meta-Analysis)
Chemical References
  • Antineoplastic Agents
Topics
  • Adolescent
  • Antineoplastic Agents (therapeutic use)
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Kidney Neoplasms (mortality, therapy)
  • Male
  • Neoplasm Recurrence, Local (mortality, therapy)
  • Neoplasm Staging
  • Salvage Therapy (methods)
  • Stem Cell Transplantation
  • Wilms Tumor (mortality, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: